Autism: the management and support of children and young people on the autism spectrum (NICE Clinical Guideline 170)

Crowe, Belinda; Salt, Alison

doi:10.1136/archdischild-2013-305468

Cited by 49 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Limited research exists on the treatment of co-morbid anxiety disorders in children with ASD, but the consensus is that CBT, with certain modifications, can be used as a treatment for anxiety [11]. The National Institute for Health and Care Excellence (NICE) and a few other reviews list some guidelines in the modification of CBT for children with ASD regarding structure and content, which will be briefly summarized in Table 1 [11,34,35]: Table 1. Guidelines regarding the modification of Cognitive Behavioural Therapy (CBT) for Autism Spectrum Disorder (ASD) according to National Institute for Health and Care Excellence (NICE) [34] and literature reviews [11,35].…”

Section: Modifications For Asdmentioning

confidence: 99%

Empowering Children with ASD and Their Parents: Design of a Serious Game for Anxiety and Stress Reduction

Carlier

Paelt

Ongenae

et al. 2020

Sensors

View full text Add to dashboard Cite

Autism Spectrum Disorder (ASD) is characterized by social interaction difficulties and communication difficulties. Moreover, children with ASD often suffer from other co-morbidities, such as anxiety and depression. Finding appropriate treatment can be difficult as symptoms of ASD and co-morbidities often overlap. Due to these challenges, parents of children with ASD often suffer from higher levels of stress. This research aims to investigate the feasibility of empowering children with ASD and their parents through the use of a serious game to reduce stress and anxiety and a supporting parent application. The New Horizon game and the SpaceControl application were developed together with therapists and according to guidelines for e-health patient empowerment. The game incorporates two mini-games with relaxation techniques. The performance of the game was analyzed and usability studies with three families were conducted. Parents and children were asked to fill in the Spence's Children Anxiety Scale (SCAS) and Spence Children Anxiety Scale-Parents (SCAS-P) anxiety scale. The game shows potential for stress and anxiety reduction in children with ASD.Sensors 2020, 20, 966 2 of 41 language. ASD is a heterogeneous condition: the profile of each child or adult with ASD is unique [4]. An estimated 1 in 132 individuals suffers from ASD [5]. As a result of these challenges, related to social functioning and communication, people with ASD often suffer from other conditions, such as mood swings and anxiety. It is estimated that up to 72% of children with ASD suffer from co-morbidities [6], however, co-morbidity rates remain largely unknown for ASD, as co-morbid conditions can be difficult to diagnose [7][8][9][10]. Depression and anxiety are two of the most common ASD co-morbidities with rates around 40 to 50% [11].Due to communication difficulties, children with ASD are often unable to express themselves when stressed or frustrated. Combined with unique symptoms in every child and overlap in symptoms of co-morbidities, it is challenging to find the appropriate response. As a result, temper tantrums are common, which can be an important cause of parental stress [1]. Determining the correct diagnosis or finding appropriate treatment is difficult due to the challenges in communication and uniqueness in symptoms [7].Empowering both the children and their parents by raising awareness of the child's anxiety and stress can result in better management of the child's temper tantrums, which can result in a decrease in stress and anxiety. The term "patient empowerment" is used in many different settings and domains, but no general definition exists. The consensus is that patient empowerment is used to describe situations where patients and users are encouraged to take control of their health management [12]. In other words, patient empowerment is enabling patients to actively understand their health [13], but also the support to restore a sense of hope, respect, self-efficacy and the drive to face seemingly insurmountable challenges [14...

show abstract

Section: Modifications For Asdmentioning

confidence: 99%

Empowering Children with ASD and Their Parents: Design of a Serious Game for Anxiety and Stress Reduction

Carlier

Paelt

Ongenae

et al. 2020

Sensors

View full text Add to dashboard Cite

show abstract

“…(GRADE B1) 46,285 Enfermedades neuropsiquiátricas R No se recomienda la IgIV en pacientes con autismo. (GRADE B4) 295,296 R Se recomiendan 2 g/kg de IgIV divididos en 2 días en niños con formas graves de los trastornos neuropsiquiátricos autoinmunitarios asociados con infecciones por estreptococos, resistentes a tratamiento convencional. (GRADE B2) 144,297,298 Usos misceláneos R La IgIV no se recomienda como tratamiento del síndrome de fatiga crónica.…”

Section: Misceláneosunclassified

Guía colombiana de práctica clínica para el uso de inmonuglobulinas en el tratamiento de reemplazo e inmunomodulación

Olivares

Olmos²,

Álvarez

et al. 2017

RAM

View full text Add to dashboard Cite

Immunoglobulins are heterodimeric proteins composed of 2 heavy chains and 2 light chains. Human immunoglobulin G (IgG) is a plasma derivative and contains more than 95% of IgG. The composition of IgG subclasses is similar to that of normal human plasma. Immunoglobulin therapy was first introduced more than 50 years ago, and its use has been described in numerous diseases. In Colombia, the importance of this immunomodulatory resource prompted the need for clinical practice guidelines to be available for its use. For this reason, a multidisciplinary group of experts was brought together and distributed in working groups, by specialties, in order to develop an initial manuscript. Systematic literature searches were undertaken; identified evidences were evaluated and classified to support a preliminary draft that was discussed, analyzed and amended. Recommendations were issued on the use of intravenous immunoglobulin in pathologies that include primary and secondary immunodeficiencies, autoimmune diseases, neurological disorders, infections, transplants and miscellaneous conditions; grades were assigned to each one of them according to the GRADE system. The final result translated into recommendations that are put forth with the purpose to inform, guide and support on optimal use of this immunomodulatory resource.

show abstract

“…Early intervention in ASD differs with regard to the underlying developmental theory, treatment targets, therapeutic methods, involvement of parents, and intervention intensity. Recent comprehensive systematic reviews [9,10] agree that the evidence base of any treatment is at maximum moderate, and improvement of core autistic symptoms has rarely been studied. Many of the studied early intervention programmes for toddlers and preschool-aged children are either complex, targeting a broad range of areas with high intensity (> 10, up to 40 h/week work with therapists) [11,12], or are highly specific with low intensity, targeting core developmental aspects, such as joint attention and symbolic play [13], parent-child interaction [14] or language abilities [15].…”

Section: Introductionmentioning

confidence: 99%

Study protocol of the multi-centre, randomised controlled trial of the Frankfurt Early Intervention Programme A-FFIP versus early intervention as usual for toddlers and preschool children with Autism Spectrum Disorder (A-FFIP study)

Kitzerow

Hackbusch

Jensen

et al. 2020

Trials

View full text Add to dashboard Cite

Background: Naturalistic developmental behavioural interventions (NDBI) have been shown to improve autismspecific symptoms in young children with Autism Spectrum Disorder (ASD). NDBI approaches, such as the ASDspecific Frankfurt Early Intervention Programme for ASD (A-FFIP), are based on ASD-specific developmental and learning aspects. A-FFIP is a low-intensity intervention which can easily be implemented in the local health care/ social welfare system. The aim of the present study is to establish 1-year efficacy of the manualised early intervention programme A-FFIP in toddlers and preschool children with ASD. It is hypothesised that A-FFIP will result in improved ASD-specific symptoms compared to early intervention as usual (EIAU). Child-and family-specific secondary outcomes, as well as moderators and mediators of outcome, will be explored. Methods/design: A prospective, multi-centre, parallel-group, randomised controlled, phase-III trial comparing A-FFIP versus EIAU. A total of 134 children (A-FFIP: 67, EIAU: 67) aged 24-66 months at baseline assessment meeting the criteria for ASD (DSM-5) will be included. The primary outcome is the absolute change of the total score of the Brief Observation of Social Communication Change (BOSCC-AT) between baseline (T2) and 1-year follow-up (T6). The treatment effect will be tested, adjusted for relevant covariates applying a mixed model for repeated measures. Secondary outcomes are BOSCC social communication and repetitive-behaviour scores, single ASD symptoms, language, cognition, psychopathology, parental well-being and family quality of life. Predictors, moderators and mediating mechanisms will be explored.

show abstract

Autism: the management and support of children and young people on the autism spectrum (NICE Clinical Guideline 170)

Cited by 49 publications

References 0 publications

Empowering Children with ASD and Their Parents: Design of a Serious Game for Anxiety and Stress Reduction

Empowering Children with ASD and Their Parents: Design of a Serious Game for Anxiety and Stress Reduction

Guía colombiana de práctica clínica para el uso de inmonuglobulinas en el tratamiento de reemplazo e inmunomodulación

Study protocol of the multi-centre, randomised controlled trial of the Frankfurt Early Intervention Programme A-FFIP versus early intervention as usual for toddlers and preschool children with Autism Spectrum Disorder (A-FFIP study)

Contact Info

Product

Resources

About